Phase II Trial of the PD-1 Antibody Nivolumab in Combination With Lenalidomide and Low Dose Dexamethasone in Patients With High-Risk Smoldering Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 29 Dec 2017
At a glance
- Drugs Dexamethasone (Primary) ; Lenalidomide (Primary) ; Nivolumab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 20 Dec 2017 Status changed from recruiting to suspended.
- 10 Jun 2017 Biomarkers information updated
- 01 Nov 2016 Status changed from not yet recruiting to recruiting.